P-glycoprotein (or P-gp1, ABCB1) expression in tumor cells is causative of multidrug
resistance through the active efflux of drugs across the cell membrane. However, the over …

The overexpression of P-glycoprotein (P-gp, ABCB1) in cancer cells often leads to multidrug
resistance (MDR) through reduced drug accumulation. However, certain P-gp-positive cells …

Multidrug resistance (MDR) of cancer tissue is a phenomenon in which cancer cells exhibit
reduced sensitivity to a large group of unrelated drugs with different mechanisms of …

Multidrug resistance (MDR) is a phenomenon in which cells become resistant to cytostatic
drugs and other substances with diverse chemical structures and cytotoxicity mechanisms …

MDR1 (multidrug resistance) P-glycoprotein (Pgp; ABCB1) decreases intracellular
concentrations of structurally diverse drugs. Although Pgp is generally thought to be an …

Multidrug resistance (MDR) seriously limits the clinical application of chemotherapy. A
mechanism underlying MDR is the overexpression of efflux transporters associated with …

Acquired resistance to chemotherapy is a major problem during cancer treatment. One
mechanism for drug resistance is overexpression of the MDR1 (multidrug resistance) gene …

Intercellular transfer of proteins is a mode of communication between cells that is crucial for
certain physiological processes. Chemotherapy is the treatment of choice for∼ 50% of all …

Multidrug resistance (MDR) is a phenomenon whereby cells confer drug resistance to
structurally and functionally unrelated compounds. P-glycoprotein (P-gp; MDR1 or ABCB1) …

In 1976, Juliano and Ling 1 reported expression of a 170 kDa protein in colchicine‐resistant
Chinese hamster ovary (CHO) cells that was absent in drug‐sensitive cells. Because this …